Satellos Bioscience Inc. announced that Alan K. Jacobs, M.D., Chief Medical Officer, has left the Company to pursue other opportunities. Satellos has engaged Jordan Dubow, M.D., to lead the development of clinical trial strategy for the Company?s lead program in Duchenne muscular dystrophy in the role of Chief Medical Advisor Dr. Dubow has more than 15 years of experience leading all stages of clinical drug development and has played a pivotal role on 16 new drug applications in the U.S. as well as numerous NDAs in Europe, Japan, Canada, and Australia. He has served as a full time or acting Chief Medical Officer for over 10 companies including Jaguar Gene Therapy, Paragon Biosciences, Avadel Pharmaceuticals, and Marathon Pharmaceuticals.

Prior to becoming a chief medical officer, he was Vice President, Clinical and Medical Affairs at Cynapsus Therapeutics and Medical Director, Neuroscience Clinical Development at Abbvie. Dr. Dubow is a board-certified neurologist and has more than 10 years of clinical experience in neurology and internal medicine. He received his M.D. and completed a neurology residency at the Northwestern University Feinberg School of Medicine.

He completed a movement disorders fellowship at a Northwestern University-affiliated hospital and a vascular neurology fellowship at New York Presbyterian/Weill Cornell Medical Center.